Silence Therapeutics (SLN) Total Liabilities (2018 - 2026)

Silence Therapeutics has disclosed Total Liabilities across 9 years of filings, most recently posting $65.7 million for Q1 2026.

• Total Liabilities for Q1 2026 came in at $65.7 million, down 9.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $65.7 million (down 9.42% YoY), and the FY2025 annual result was $69.1 million, up 0.77% from the prior year.
• Total Liabilities came in at $65.7 million for Q1 2026 at Silence Therapeutics, down from $69.1 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $100.2 million in Q4 2022 to a low of -$156.8 million in Q1 2024.
• The 5-year median for Total Liabilities is $69.1 million (2025), against an average of $17.2 million.
• Across the five-year window, Total Liabilities dropped 27.99% in 2024 and surged 157.4% in 2025, its largest moves.
• Silence Therapeutics' Total Liabilities stood at $100.2 million in 2022, then retreated by 4.91% to $95.3 million in 2023, then decreased by 27.99% to $68.6 million in 2024, then climbed by 0.77% to $69.1 million in 2025, then decreased by 4.94% to $65.7 million in 2026.
• The last three Total Liabilities figures came in at $65.7 million (Q1 2026), $69.1 million (Q4 2025), and $72.7 million (Q3 2025), per Business Quant data.